Poor
Not Aligned
Patient Risk:
High
Summary
Multiple interaction claims (ibuprofen, naproxen, diphenhydramine, pseudoephedrine) are not supported by the provided prescribing information sections. Only general TG indication/mechanism and increased bleeding risk with anticoagulants/antiplatelet agents are supported.
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is indicated for patients with elevated triglyceride (TG) levels in the specific labeled populations/adjunctive contexts.
Supported by Section 1 INDICATIONS AND USAGE.
Vascepa works to reduce TG levels.
Supported by Section 1 INDICATIONS AND USAGE and Section 12.1 Mechanism of Action.
Vascepa is associated with increased bleeding risk, particularly with concomitant anticoagulants/antiplatelet agents.
Supported by Section 5.3 Bleeding and Section 7.1.
Unsupported Statements
Vascepa can increase the risk of bleeding when taken with ibuprofen.
No provided label section mentions ibuprofen or NSAID-specific interaction; only general bleeding risk and bleeding risk with anticoagulants/antiplatelet agents are described.
Vascepa can increase the risk of bleeding when taken with naproxen.
No provided label section mentions naproxen or NSAID-specific interaction.
Antihistamines such as diphenhydramine can increase the risk of dizziness and drowsiness when taken with Vascepa.
No provided label section mentions diphenhydramine, antihistamines, dizziness, drowsiness, or any related interaction.
Decongestants such as pseudoephedrine can increase the risk of high blood pressure when taken with Vascepa.
No provided label section mentions pseudoephedrine, decongestants, or high blood pressure as an interaction.
The answer states that it is not recommended to take Vascepa with ibuprofen.
No provided label section contains an ibuprofen-specific recommendation/avoidance statement.
The answer states that it is not recommended to take Vascepa with diphenhydramine.
No provided label section contains a diphenhydramine-specific recommendation/avoidance statement.
The answer states that it is not recommended to take Vascepa with pseudoephedrine.
No provided label section contains a pseudoephedrine-specific recommendation/avoidance statement.
Vascepa can interact with OTC medications, leading to adverse effects or reducing its effectiveness.
Provided sections discuss interactions/bleeding risk with anticoagulants and antiplatelet agents; they do not establish a general OTC interaction rule or reduction in effectiveness.
Contradictions
AI Statement
The answer states that it is not recommended to take Vascepa with ibuprofen/diphenhydramine/pseudoephedrine.
Label Reference
No contradicting label statement is present in the provided sections; these statements are instead unsupported (not label-supported), not directly conflicting.
Important Omissions
If making an interaction/avoidance statement, the label-supported interaction class in the provided sections is concomitant anticoagulants/antiplatelet agents requiring bleeding monitoring; the provided claims focus on specific non-supported agents instead.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Unsupported, drug-/ingredient-specific interaction avoidance claims (ibuprofen, naproxen, diphenhydramine, pseudoephedrine) could mislead decision-making; the provided label sections only support increased bleeding risk with anticoagulants/antiplatelet agents.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple interaction claims and avoidance recommendations are not supported by the provided prescribing information sections.
Suggested Improvement
Restrict interaction statements to what is supported in the provided label (e.g., increased bleeding risk and monitoring with concomitant anticoagulants and/or antiplatelet agents) and avoid agent-specific claims for ibuprofen, naproxen, diphenhydramine, and pseudoephedrine unless the prescribing information explicitly addresses them.